2 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CEP-701 (Lestaurtinib) in Myelofibrosis CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 60 | 2008-04-01 | 2014-11-26 |
| Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer sargramostim, amifostine trihydrate, carboplatin - Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ | Phase 1 | Unknown | The Cleveland Clinic | 30 | 1997-11-01 | 2013-12-19 |
Polycythemia Vera (2) · Primary Myelofibrosis (2) · Thrombocythemia, Essential (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Drug-Related Side Effects and Adverse Reactions (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1)
Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Bone Marrow Diseases (2) · Bone Marrow Neoplasms (2) · Hematologic Diseases (2) · Hematologic Neoplasms (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Neoplasms (2) · Neoplasms by Site (2) · Amyloidosis (1) · Blood Protein Disorders (1) · Carcinogenesis (1) · Cardiovascular Diseases (1)
Amifostine (1) · Carboplatin (1) · Cyclophosphamide (1) · lestaurtinib (1) · sargramostim (1)
Ronald Hoffman (1) · The Cleveland Clinic (1)
United States (2)
George Thomas Budd, MD (1) · Ronald Hoffman, MD (1)
P01CA108671 (1)